In his new role, Adams will be responsible for strengthening the company’s R&D operations and commercial infrastructures to support NLX-P101.
Prior to joining Neurologix, Adams worked as the president and CEO of Inspire Pharmaceuticals and was responsible for entire commercialization of prescription pharmaceutical products.
Additionally, the company has also appointed Andrew Koven as the president and chief administrative officer.